Orchestra BioMed to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference

Canaccord Genuity MedTech and Diagnostics Forum

Date: November 21, 2019
Time: 9:00 AM ET

31st Annual Piper Jaffray Healthcare Conference

Date: December 4, 2019
Time: 2:10 PM ET

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine. The Company partners with established market leaders to drive global commercialization of its products, establishing multiple long-term potential revenue streams and supporting further product development. Its current product pipeline was organically developed and features Virtue^® Sirolimus-Eluting Balloon (SEB) for the treatment of artery disease, the leading cause of death worldwide, and BackBeat Cardiac Neuromodulation Therapy^™ (CNT^™) for the treatment of hypertension, the leading contributing risk factor for death worldwide. The Company has a global strategic partnership with Terumo Corporation, one of the world’s largest medical device companies, for the development and commercialization of Virtue SEB. Orchestra BioMed’s business model optimizes capital efficiency and cash flow by developing therapies with a high probability of success that fulfill a specific need, fit within current clinical workflow and deliver health-economic value. Orchestra BioMed is led by a multi-disciplinary team with a long track record of successful product development.